Figure 4: Soluble CCR3 and CCR5 activity in the supernatants of control and IL-1β-treated RIN-5AH cells as assessed by ELISA. At 8 hours, a significant inhibition of CCR5 release was obtained after IL-1β addition, whereas no inhibition of CCR3 release was observed.